

APSA-ASCEPT JOINT SCIENTIFIC MEETING 5-8 DECEMBER 2017 BRISBANE CONVENTION & EXHIBITION CENTRE



Optimising medicines for optimal patient outcomes

www.apsa-ascept2017.com

SYMPOSIUM 1: Cannabinoids for patients: Getting the pharmacology right first time

Dr Catherine Lucas, University of Newcastle



Catherine Lucas is a lecturer in clinical pharmacology at the University of Newcastle and is a dual accredited clinical pharmacologist and nuclear medicine physician. She studied pharmacy and subsequently medicine at the University of Queensland. Her research interests include medicinal cannabis, pharmacokinetic-guided individualisation of drug-dosing regimens, medical education and theranostics.

Prof Noel Cranswick, Melbourne University



Noel Cranswick is a General Paediatrician at the Royal Children's Hospital. He is also the Director of Clinical Pharmacology and the Australian Paediatric Pharmacology Research Unit as well as an Associate Director of the Melbourne Children's Trials Centre. He is fully trained in both paediatrics and clinical pharmacology and a legal graduate. Noel has extensive clinical trial experience in both adult and children. He has been an investigator on over 180 clinical drug trials and is familiar with early phase trial methodology and ICH GCP requirements. He has been an advisor to both Government and Industry and continues to evaluate new drug applications for the Australian Therapeutic Drugs Administration. He has also been a member of the Committee for the selection of Essential Medicines for the World Health Organisation.

Dr Peter Galettis, University of Newcastle



Dr Galettis currently holds the position of Head of the Clinical Pharmacology Laboratory and Senior Lecturer at the University of Newcastle. Previously he held positions at SA pathology, where he was responsible for the development and implementation of new assays for the Division of Chemical Pathology; the Cancer Care Centre, St George Hospital where he led the Cancer Pharmacology and Therapeutics group; and Research Fellow at the University of Auckland. His research interests are entirely within the field of clinical pharmacology and toxicology, specializing in assay development for use in drug monitoring, focussing on anticancer agents and drugs of abuse.

Dr Zheng Liu, The University of Melbourne



Zheng had previously worked on mathematical modelling in chemical engineering field and was awarded his engineering PhD in 2015. His research is currently focused on pharmacometrics, e.g. development of pharmacological models, modelling of data and the design of clinical studies. Zheng is also actively involved in a WHO project, focusing on propagating Exclusive Breastfeeding in low-income countries. His role is mainly to develop the breastfeeding mathematical model and measure quantitatively the Exclusive Breastfeeding levels of the mothers.

Assoc Prof Jennifer Schneider, University of Newcastle



Jennifer is an Associate Professor (Pharmacy) in the School of Biomedical Sciences and Pharmacy at the University of Newcastle, teaching courses in pharmacokinetics, pharmaceuticals, oncology and palliative care. She is internationally recognised for her research in palliative care and has worked in other areas of research including toxicology, developing new pharmacy practice models and using technology in teaching. Her current research is focussed on exploring the feasibility of novel blood sampling techniques for use in therapeutic drug monitoring of chemotherapy drugs and investigating the pharmaceuticals and pharmacokinetics of cannabinoids.

APSA-ASCEPT

JOINT SCIENTIFIC MEETING

5-8 DECEMBER 2017

BRISBANE CONVENTION & EXHIBITION CENTRE



Optimising medicines for optimal patient outcomes

www.apsa-accept2017.com

SYMPOSIUM 2: Mice, modelling and post-marketing surveillance to inform medication efficacy and safety

Dr John Mach, Kolling Institute of Medical Research; The University of Sydney



John Mach is currently a Postdoctoral Research Fellow at the Laboratory of Ageing and Pharmacology, Kolling Institute and aims to use preclinical models to guide clinical prescribing for older patients. He earned his PhD at USYD in 2016, supervised by Professor Sarah Hilmer, using preclinical models to investigate risk of drug induced liver injury in old age. After completing his PhD, John accepted a position as a Postdoctoral Research Fellow at the Laboratory of Ageing and Pharmacology and his work now focuses on utilising preclinical models to understand the risks of single and multiple concurrent medicines in old age.

Prof Carl Kirkpatrick, Monash University



Professor Carl Kirkpatrick is the Director of the Centre for Medicines Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University. Since receiving his Doctor of Philosophy (Medicine) from the University of Otago (NZ) in 2002, Carl has worked at the University of Queensland and more recently Monash University. Carl has extensive knowledge in the area of PK/PD modelling and the factors that alter these processes, pre-clinical and clinical drug development, and clinical applications to optimization of therapy. He has worked on projects and produced publications across a number of therapeutic areas including diabetes, cardiovascular disease, cancer, aged/frailty, and infectious diseases (bacteria, viruses, and fungi)

Dr Danijela Gnjidic, The University of Sydney



Dr Danijela Gnjidic (BSc (Hons) MPH PhD) is a Research Fellow and Lecturer in Pharmacy Practice at the Faculty of Pharmacy, University of Sydney. Her research expertise is in clinical and geriatric pharmacology, clinical studies on polypharmacy, high risk prescribing, deprescribing (drug withdrawal), pharmacoepidemiology, and the quality use of medicines in older adults. Her academic track

records includes over 90 publications, 2-book chapters, and \$3.2M in research funding including the Australian National Health and Medical Research (NHMRC) project grants, NHMRC Early Career Fellowship, grants from Alzheimer's Australia, NSW Health and Cochrane.

Assoc Prof Simon Bell, Monash University



Dr Simon Bell is a NHMRC Dementia Research Leadership Fellow and Associate Professor, Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University. He is also Adjunct Professor of Geriatric Pharmacotherapy, University of Eastern Finland; and Adjunct Associate Professor, Sansom Institute, University of South Australia. Dr Bell has published more than 180 articles in peer-reviewed scientific journals, primarily related to the use of medicines in older people. Dr Bell is a Chief Investigator of the NHMRC Cognitive Decline Partnership Centre and the NHMRC Centre for Research Excellence in Frailty and Healthy Ageing. He is the inaugural chair of the Pharmacoepidemiology Special Interest Group of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT). He was awarded the Alzheimer's Australia Resthaven Dementia Research Award in 2013 and ASCEPT Denis Wade Johnson & Johnson New Investigator Award in 2014. He is Associate Editor of the Journal of Pharmacy Practice and Research.

A/Prof Christine Lin, The University of Sydney



Associate Professor Christine Lin is Principal Research Fellow at Musculoskeletal Health Sydney, Sydney School of Public Health, The University of Sydney where she co-leads the back pain research theme. She is also an NHMRC Career Development Fellow. Christine's research focuses on the effectiveness and cost-effectiveness of pharmacological and physical treatments for musculoskeletal conditions. She has been awarded >\$3.5million in research funding and has >100 publications, including in prestigious journals such as NEJM, Lancet, JAMA and BMJ.

APSA-ASCEPT
JOINT SCIENTIFIC MEETING
5-8 DECEMBER 2017
BRISBANE CONVENTION & EXHIBITION CENTRE



Optimising medicines for optimal patient outcomes

www.apsa-ascept2017.com

SYMPOSIUM 3: Optimising teaching to enhance student outcomes

Assoc Prof Susan Rowland, The University of Queensland



Associate Professor Susan Rowland completed a BSc Hons and PhD at the University of Sydney, Australia, and a Human Frontiers in Science Postdoctoral Fellowship at the University of Connecticut, USA. She is currently Deputy Director of the Institute for Teaching and Learning Innovation (ITaLI) and a teaching-focused faculty member in School of Chemistry and Molecular Biosciences (SCMB) at the University of Queensland, Australia. Susan has been a Manning Clark Fellow, an American Society for Microbiology Biology Scholar, a UQ Teaching Fellow, and is a UQ Fellow for 2017. She has won multiple awards for her teaching, including an Australian Award for University Teaching (2014) and the 2014 Australian Society for Biochemistry and Molecular Biology Beckman Coulter Award for Teaching Excellence. She is a Senior Fellow of the Higher Education Academy (2016). Her current UQ Teaching Fellowship focuses on Work Integrated Learning for Science students. Susan teaches biology, biochemistry, and molecular biology at undergraduate and postgraduate level at the University of Queensland. Her Scholarship of Teaching and Learning focuses on the development of student professionalism through immersion in authentic scientific practice. She has particular interests in undergraduate research experiences and science communication.

Dr Rosa McCarty, The University of Melbourne



Rosa McCarty is a Lecturer (Teaching Specialist) in the Department of Pharmacology & Therapeutics, and Teaching Fellow in Stem Cells & Regenerative Medicine with the Centre for Stem Cell Systems, at The University of Melbourne. Rosa completed her Bachelor of Science and Doctor of Philosophy (Medicine) at The University of Adelaide, and was a post-doctoral scientist Australian Stem Cell Centre with a research focus on adult stromal stem cell biology. A teaching academic for the last seven years, Rosa is a passionate educator with particular interest in developing research skills and graduate attributes in undergraduate students, practical-based teaching, and peer assessment.

Dr Karen Luetsch, The University of Queensland



Karen is teaching in the Postgraduate Clinical Pharmacy Program at The University of Queensland. Karen has a particular interest in how pharmacists and other health professionals communicate with each other and the people they care for. She is designing of face-to-face and online learning programs, which aim at enhancing pharmacists' patient-centred and interprofessional practice through successful communication. Karen's research interests are in the evaluation of teaching and learning and social pharmacy, with many projects originating from reflections on her current and past practice as a pharmacist and clinical educator.

APSA-ASCEPT JOINT SCIENTIFIC MEETING 5-8 DECEMBER 2017 BRISBANE CONVENTION & EXHIBITION CENTRE

apsa
Australian Pharmacology & Therapeutics Association

ASCEPT



Optimising medicines for optimal patient outcomes

www.apsa-ascept2017.com

SYMPOSIUM 4: Novel aspects of drug metabolising enzymes-structure, function and regulation

Prof John Miners and Dr Pramod Nair, Flinders University



John Miners holds BSc, MSc, PhD and DSc degrees. He is a Fellow of the Australian Academy of Science and an Honorary Fellow of the Royal Society of New Zealand. He is currently a Matthew Flinders Distinguished Professor in the Flinders University School of Medicine, having

previously served as Professor and Head of the Department of Clinical Pharmacology. His broad research interest is drug and chemical metabolism in humans, particularly sources of variability in drug elimination and its pharmacokinetic and therapeutic consequences. Current projects include: (i) structure-function relationships and genetic polymorphisms of human UDP-glucuronosyltransferases and cytochromes P450; (ii) *in vitro* and computational models for the prediction of drug and chemical metabolism parameters *in vivo*; (iii) drug-drug interactions; and (iv) metabolomics.

Dr Pramod Nair, Flinders University



Dr Pramod Nair is a Research Fellow in Computational and Molecular Pharmacology at Flinders University. He is a recipient of Australian Government Endeavour International Postgraduate Research Scholarship for his doctoral training and was awarded PhD in Medicinal

Chemistry from the University of Queensland (UQ). In 2012, he joined the laboratory of Professor John Miners as a Post-Doctoral Fellow. He has broad research interests in the area of pharmaceutical sciences, particularly, in drug design, drug metabolism and drug-drug interactions. His recent work focuses on reconciling theoretical and experimental approaches for understanding the mechanisms of ligand recognition in cytochrome P450s.

Prof Michael Murray, The University of Sydney



Michael Murray is in Discipline of Pharmacology at The University of Sydney. He completed a PhD in Pharmaceutical Chemistry at the University of Sydney and a postdoctoral fellowship at Cornell University in Ithaca, New York. He was an NHMRC Principal Research Fellow before entering

academia at UNSW. In 2003 he returned to the University of Sydney's Faculty of Pharmacy and relocated to Pharmacology in 2013. His major

research interests have been in drug metabolism by CYPs and mechanisms of drug and chemical toxicity. More recently, his research has focused on the development of novel lipid analogues as anticancer agents.



Dr Robyn Meech, Flinders University

Dr. Meech is a pharmacologist and stem cell biologist with extensive experience in drug metabolizing enzymes as well as mechanisms of gene regulation, cell signalling and cell and stem cell biology. She trained at Flinders University of South Australia and the Scripps Research Institute in San Diego, California. She directs a program of study on UDP-glycosyltransferases (UGTs) focused on how these enzymes are regulated and their roles in metabolizing drugs, xenobiotics and endogenous metabolites. The latter is of particular interest as these metabolites include many transcription factor ligands and signaling molecules that influence cell and stem cell behavior and may contribute to the development of cancer and degenerative disease. She has received 3 NIH grants in support of her work and recently completed an ARC Future Fellowship. She directs a current NHMRC project grant on UGTs in cancer progression and drug resistance.



Dr Neville Butcher, The University of Queensland

Neville Butcher is a Research Fellow in the School of Biomedical Sciences at The University of Queensland. He was awarded his PhD in 2001 from the University of Western Australia. He then worked as a post-doctoral scientist at the Laboratory for Cancer Medicine, Western Australian Institute for Medical Research, before relocating to The University of Queensland in 2004. He is a molecular pharmacologist with research interests in drug metabolism and pharmacogenetics, specifically the role of the arylamine N-acetyltransferases in cancer development and the function of cytosolic sulfotransferases in the brain.

APSA-ASCEPT
JOINT SCIENTIFIC MEETING
5-8 DECEMBER 2017
BRISBANE CONVENTION & EXHIBITION CENTRE




Optimising medicines for optimal patient outcomes

www.apsa-accept2017.com

Prof Rodney Minchin, The University of Queensland

Following his PhD at the University of Western Australia, Prof Minchin studied at the NIH in Washington DC where he trained in molecular and cell biology, animal physiology and clinical studies in carcinogenesis and cancer research. He joined the University of New South Wales as a Queen Elizabeth II fellow before returning to the University of Western Australia as an academic. In 2003, Prof Minchin



accepted the Chair of Molecular Pharmacology at the University of Queensland. His group has been responsible for many of the seminal discoveries into the genetics and molecular regulation of the arylamine N-acetyltransferases and aryl sulfotransferases through ongoing collaborations with colleagues at Oxford, Paris and Toronto. In recent years, his research has included the understanding of the pharmacology of nanomedicines and their disposition.

APSA-ASCEPT JOINT SCIENTIFIC MEETING 5-8 DECEMBER 2017 BRISBANE CONVENTION & EXHIBITION CENTRE



Optimising medicines for optimal patient outcomes

www.apsa-ascept2017.com

SYMPOSIUM 5: Why is polypharmacy increasing in aged care facilities and what can we do about it?

Ms Natali Jokanovic, Monash University



Natali Jokanovic is a PhD candidate at the Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University. She is also a practicing clinical pharmacist at Alfred Health. Her PhD research seeks to provide a better understanding of the

prevalence, factors and outcomes associated with polypharmacy in residential aged care facilities. Her research interests include pharmacoepidemiology, public health and the quality use of medicines.

Dr Justin Turner, University of Montreal



Dr Justin Turner is a Postdoctoral Fellow at the Université de Montréal and the Assistant Director of the Canadian Deprescribing Network. Justin's experiences as a pharmacist in hospitals, community pharmacy and residential aged care drive his passion for improving patient relevant outcomes by optimizing medication use. His main

research focuses on the patient-centered process of deprescribing, in which unnecessary or potentially inappropriate medications are ceased under the guidance of a health care professional. Justin is currently coordinating a number of pragmatic cohort randomised controlled trials in primary care across Canada.

Mr David Freemantle, Fred IT Group



David joined Fred IT Group in 2008 having worked for Accenture, Deloitte and Ajilon specialising in Strategy and Change Management. His experience in large system implementations throughout Australia, Asia, USA and Canada saw David join Fred to lead the development of Australia's leading

ePrescription exchange, eRx Script Exchange. Utilised by over 4,800 pharmacies and 22,000 GPs, eRx has transacted over 2 billion electronic prescriptions since inception. He has since lead the development and operation of the Commonwealth Government's National Prescription and Dispense Repository and continues to lead the development of eHealth solutions to create efficiencies in the health system while providing patients with better health outcomes.

Dr Janet Sluggett, Monash University



Dr Janet Sluggett is a Research Fellow at the Centre for Medicine Use and Safety, Monash University, contributing to the NHMRC Cognitive Decline Partnership Centre project to optimise quality use of medicines for people with cognitive and related functional decline. Janet's

research interests include quality use of medicines, pharmacoepidemiology, quality improvement, and cognitive decline. As an early career pharmacy researcher embedded within an aged care organisation, Janet is passionate about improving care and innovative models of practice in aged care. She is currently implementing a cluster randomised controlled trial to optimise medication use across eight South Australian residential aged care facilities.

APSA-ASCEPT JOINT SCIENTIFIC MEETING 5-8 DECEMBER 2017 BRISBANE CONVENTION & EXHIBITION CENTRE



Optimising medicines for optimal patient outcomes

www.apsa-ascept2017.com

SYMPOSIUM 6: New strategies to treat chronic inflammatory diseases

Prof Emilio Badoer, RMIT University



Professor Badoer is Professor of Neuropharmacology in the School of Health and Biomedical Sciences RMIT University. He has made substantial contributions in the understanding of the central nervous system in sympathetic nerve regulation and leads the Neuropharmacology and Neuroinflammatory Research Laboratory. His laboratory utilises pharmacological, neurophysiological and neuroanatomical techniques to tackle problems using both in vitro and in vivo preparations. This multi-pronged approach is a major strength in the investigation of the central regulation of autonomic function in conditions like heart failure, obesity and insulin resistance. Professor Badoer also has teaching commitments in pharmacology, physiology and drug development.

Prof Christopher Sobey, La Trobe University



Chris Sobey is an NHMRC Senior Research Fellow and Professor in Physiology at La Trobe University. He has more than 170 publications from his studies of vascular diseases involving oxidative stress and inflammation – especially stroke, atherosclerosis and hypertension. His current work is investigating the inflammatory mechanisms occurring in the brain after stroke in order to identify and develop new treatments for stroke patients. Novel approaches include systemic cell therapy, Th2 cytokines and estrogen receptor binding drugs.

Prof Mary Collins, The University of Sydney



Professor Mary Collins (Chebib) was awarded her PhD from Griffith University in 1994. After a six-year postdoctoral position at the Department of Pharmacology, the University of Sydney, she started as a lecturer in the Faculty of Pharmacy and promoted to Professor in 2012. Mary has received a number of awards including the ASCEPT New Investigator Award, RACI Biota Award, entry as Fellow of the RACI, and the University of Sydney Faculty of Pharmacy Higher Degree Supervision Award. She served as a member of the Pharmaceutical Subcommittee of the Australian Drug Evaluation Committee for the TGA, associate editor for *Amino Acids*, Chair of the RACI Biomolecular Chemistry Division and RACI NSW Branch President. She has over 120 peer reviewed articles, competitive grant funding of over \$Aus10 million career-wide, and graduated 15 higher degree research students as primary supervisor.

Assoc Prof Ross Vlahos, RMIT University



Associate Professor Ross Vlahos is a Principal Research Fellow and Head of the Respiratory Research Group in the School of Health and Biomedical Sciences, RMIT University. His research aims to identify novel strategies for the prevention and treatment of COPD and its co-morbidities with a focus on the cellular and molecular pathways that underpin cigarette smoke-induced lung inflammation and damage. Ross has co-authored more than 80 publications in peer reviewed journals, has had continuous NHMRC funding since 2001 and has played a major role in commercially funded work that has confidentiality/patent agreements. He has served on NHMRC Grant Review Panels, various conference committees and Chaired sessions at international meetings.

APSA-ASCEPT
JOINT SCIENTIFIC MEETING
5-8 DECEMBER 2017
BRISBANE CONVENTION & EXHIBITION CENTRE



Optimising medicines for optimal patient outcomes

www.apsa-ascept2017.com

SYMPOSIUM 7: Novel targets for the treatment of pain

Dr Wendy Imlach, Monash University



Dr Wendy Imlach is an NHMRC career development fellow and head of the Pain Mechanisms group at Monash University in the Department of Physiology and Monash Biomedicine Discovery Institute. Her research is focused on neural circuits in the spinal cord that are activated in chronic pain, in an effort to identify new therapeutic targets. She obtained her PhD in Pharmacology from the University of Otago, followed by postdoctoral positions at Columbia University, University of Queensland and the University of Sydney. Wendy has a background in neuropharmacology, synaptic physiology and neural circuitry and her laboratory investigates dorsal horn circuitry and nociceptive signalling.

Dr Sulayman Dib-Hajj, Yale University, USA



Dr. Dib-Hajj is a Senior Research Scientist in the Yale School of Medicine and Graduate School, and an Associate Director for the Center for Restoration of Nervous System Function, the Veterans Administration Medical Center in West Haven, Connecticut. He received his undergraduate education from the American University of Beirut, Lebanon, and his PhD from the Ohio State University, Columbus, OH. His recent research has centered on the molecular basis of excitability disorders in humans including pain, with a focus on the role of voltage-gated sodium channels in the pathophysiology of these disorders, and as targets for new therapeutics.

Assoc Prof Stuart Brierley, Flinders University; SAHMRI



A/Prof Stuart Brierley is an NHMRC R.D Wright Biomedical Fellow at Flinders University. He is head of the Visceral Pain Research Group, located at the South Australian Health and Medical Research Institute (SAHMRI). A/Prof Brierley is an international authority on the different afferent classes innervating the gut, the receptors/channels underlying their function, the interaction of these receptors/channels with inflammatory mediators, and how this changes in acute and chronic pain. A/Prof Brierley has a proven track record in coordinating multi-faceted research programs for high-impact publications in journal such as *Nature*, *Nature Communications*, *Nature Reviews Gastroenterology and Hepatology*, *Gastroenterology*, *Gut*, *Pain* and *The Journal of Neuroscience*.

Dr Kate Poole, University of New South Wales



Dr Kate Poole is a lecturer at UNSW Sydney, School of Medical Sciences. Kate is studying how cells can sense their physical environment, with a focus on the role of mechanosensitive ion channels. Kate received her PhD from the University of Adelaide in 2002 before relocating to Germany for her postdoctoral studies, initially at the Max Planck Institute for Molecular Cell Biology and Genetics in Dresden and then the Max Delbrück Center for Molecular Medicine in Berlin. Kate received the Cecile Vogt Fellowship in 2012 to establish her independence at the Max Delbrück Center before returning to Sydney in 2016.

APSA-ASCEPT JOINT SCIENTIFIC MEETING 5-8 DECEMBER 2017 BRISBANE CONVENTION & EXHIBITION CENTRE



Optimising medicines for optimal patient outcomes

www.apsa-ascept2017.com

SYMPOSIUM 8: Improving Biomolecule behaviour

Dr Fiona Simpson, The University of Queensland



Fiona completed her PhD on cellular trafficking at the University of Cambridge, UK. She was then a Wellcome Trust Prize Post-doctoral fellow at The Scripps Research Institute, La Jolla, working on trafficking and endocytosis of RTKs. Fiona is currently a Fellow of the Queensland Head and Neck Cancer Centre. The Simpson lab research program is focused directly on the translation of research findings into new cancer therapies and has generated a novel method for antibody-mediated cancer therapy and associated companion diagnostic methods which are covered by three international patent applications. Fiona was the Lead scientific investigator on a Phase I proof of concept study of the novel therapy in head and neck cancer (HREC/15/QPAH/48), now successfully completed and the Lead scientific Investigator on forthcoming Phase II clinical trials in advanced cancer.

Dr Charlotte Williams, CSIRO



Dr Charlotte Williams is a Senior Research Scientist within the Biomedical Manufacturing Program at CSIRO. Dr Williams has been with CSIRO since 2009, and is currently the Team Leader for Bioconjugation Chemistry. Her research interests include investigations into unique and interesting methods to conjugate small molecules, proteins or polymers to large proteins or antibodies. Within the program Dr Williams has led a multi-disciplinary project, involving the use of RAFT polymerisation for biomedical applications, a project with external funding from the Science and Industry Endowment Fund (SIEF). Dr Williams gained industrial experience at Johnson Matthey (UK) before working for Starpharma Pty. Ltd. (Australia) where she worked for over 5 years as a Senior Research Chemist and Research Manager. Dr Williams has been a member of both the ACS and RSC and is the current treasurer for the RACI Bioactive Discovery and Development Group. Expertise in synthetic chemistry and conjugation of small molecules, proteins and antibodies, and experience with polymer synthesis and polymer bioconjugation.

Dr Michael Foley, La Trobe University



Associate Professor Michael Foley is the founding scientist of AdAlta and a key inventor of the AdAlta technology. Mick completed his Bachelor of Science Degree in Microbiology and PhD in Biophysics of Parasitic Helminths. Upon completion of his PhD he was awarded a Wellcome Training Fellowship and worked at the Walter and Elisa Hall Institute (Melbourne, Australia). After a short period as a Wellcome Research Fellow at the University of Edinburgh, Mick returned to the Department of Biochemistry at La Trobe University. In 1995 he was awarded an ARC QEII Fellowship where he established the phage display of antibodies and peptide technology as a means of answering fundamental questions of immunity to infectious diseases, particularly malaria of which he was an internationally recognized leader. Having published over 70 scientific publications, Mick has received funding from ARC, NHMRC, NIH (USA) and the Bill and Melinda Gates Foundation. In 2007 he was founding scientist and is currently CSO of AdAlta.

Dr Richard Clarke, The University of Queensland



Dr Richard Clark is a Senior Research Fellow and Head of the Peptide Chemical Biology Lab at the School of Biomedical Sciences. His research program focuses on the discovery and structure/ activity relationships of biologically active peptides and the development of these molecules as novel molecular tools and drug leads. In particular, he is interested in discovering novel naturally-occurring disulfide-rich peptides and then using molecular design approaches to understand and improve the pharmacological properties of these molecules.

APSA-ASCEPT JOINT SCIENTIFIC MEETING 5-8 DECEMBER 2017 BRISBANE CONVENTION & EXHIBITION CENTRE



Optimising medicines for optimal patient outcomes

www.apsa-ascept2017.com

SYMPOSIUM 9: The ethics of selling or recommending complimentary medicines

Prof Eleanor Milligan, Griffith University



Eleanor Milligan is a Professor of Ethics and Professional Practice at Griffith University. She is the Deputy Dean of Clinical Education and chair of Griffith University HREC. She has a strong multidisciplinary background in Science (BSc), Education (GradDipEd) and Humanities (BA, PhD). In addition to her substantive role, she contributes to a number of national and state-wide bodies as a: Director of Australian Medical Council (AMC), Member of the Medical Board of Qld (Chair of Notifications Committee), former Member of NHMRC Australian Health Ethics Committee (AHEC) and Chair of an NHMRC national project developing clinical ethics resources for Australian healthcare workers, Member of AMAQ – Ethics and Medico-legal, and Policy Committees, former Public Assessor for QCAT, former Chair of Metro South HREC.

Dr Geraldine Moses, Mater Hospital; The University of Queensland



Geraldine Moses is a doctor of clinical pharmacy specialising in drug information based in the Academic Practice Unit of the Mater Public Hospital in Brisbane. She holds the position of Adjunct Associate Professor in the University of Queensland's School of Pharmacy and also works for the Australian Dental Association providing a national drug information service called "Pharma-Advice."

She also consults to organisations such as the Department of Veterans Affairs, the Commission for Safety in Quality in Health Care, the New Zealand Dental Association and the Queensland Office of Health Ombudsman. Geraldine has received many honours and awards including in 2002 she was named the Pharmaceutical Society of Australia's Pharmacist of the Year.

Dr Adam La Caze, The University of Queensland



Adam's current position is Lecturer, School of Pharmacy, University of Queensland. He is a clinical pharmacist with a PhD in philosophy of science. Adam's research focuses on the philosophy of science, especially the contribution that philosophy of science can make to problems that arise in healthcare.

Assoc Prof Laetitia Hattingh, Griffith University



A/Prof Laetitia specialises in pharmacy practice research and teaching with a special interest in pharmacy law and ethics. She has authored more than 60 peer reviewed articles and is an author of Australian Pharmacy Law and Practice, the only text of its kind to address pharmacy practice in all its facets in the unique context of the Australian legal framework. Before joining academia Laetitia worked in various health care settings, including hospital and community pharmacy practice and pharmaceutical governance. She has a broad range of experience with regard to the pharmacy profession and medication management.

APSA-ASCEPT
JOINT SCIENTIFIC MEETING
5-8 DECEMBER 2017
BRISBANE CONVENTION & EXHIBITION CENTRE



Optimising medicines for optimal patient outcomes

www.apsa-ascept2017.com

SYMPOSIUM 10: The blood-brain barrier: A regulator of CNS drug access and disease progression


Prof William Elmquist, University of Minnesota USA



William F. Elmquist is currently Professor and Director of the Brain Barriers Research Center, at the University of Minnesota, Department of Pharmaceutics. He received his pharmacy degree at the University of Florida, and Pharm.D. and Ph.D. (pharmacokinetics) from the

University of Minnesota. His research has studied the influence of active efflux transporters in the blood-brain barrier (BBB) on CNS drug distribution. An important project currently underway is examining the determinants of anticancer drug permeability in the blood-brain barrier to improve the treatment of brain tumors. Long-term objectives of Dr. Elmquist's research include examining expression and regulation of transport systems in key tissues that influence drug disposition, and how variability in expression, either genetically or environmentally controlled, may contribute to variability in drug response in the patient. Dr. Elmquist has long been a consultant to the pharmaceutical industry and the NIH, served on many journal editorial boards, and is a Fellow of the American Association of Pharmaceutical Scientists (AAPS).

Prof Cheryl Wellington University of British Columbia, Canada



Dr. Wellington, Professor at the University of British Columbia, integrates research on genetic and environmental risk factors for dementia, with particular attention to lipoprotein metabolism, cerebrovascular dysfunction, and traumatic brain injury. Over the past

14 years, her laboratory has used a variety of genetic and pharmacological approaches to show that the amount of fats carried on apoE regulates clearance of beta-amyloid peptides, which are neurotoxic species that accumulate as amyloid in the AD brain. She has also demonstrated that apoE plays additional critical roles in diffuse axonal injury after closed-head traumatic brain injury TBI and in endothelial function. The newest area of research in Dr. Wellington's laboratory explores tissue engineered human cerebral blood vessels as model to investigate lipoprotein mediated beta-amyloid clearance across cerebrovasculature.

Prof Michal Toborek, University of Miami, USA



Michal Toborek is a Leonard M. Miller Professor of Biochemistry and Molecular Biology. Prior to getting a PhD (1989) in Biochemistry from the Silesian School of Medicine in Katowice, Poland, he obtained an MD degree in 1985 from the same institution. After completion of his

PhD degree, he moved to the University of Kentucky for his post-doctoral work and gradually rose to the ranks. In 2011, we moved to the University of Miami Miller School of Medicine. His main research interest is focused on the involvement of the blood-brain barrier (BBB) in the pathomechanisms of cerebrovascular and neurodegenerative disorders.

Prof Gregory Bix, University of Kentucky, USA



Gregory Bix, M.D., Ph.D., F.A.H.A. completed his clinical and research training at Baylor College of Medicine, the University of Pennsylvania, and Thomas Jefferson University. He is currently the Director of the Center for Advanced Translational Stroke Science and the Paul G. Blazer, Jr. endowed Stroke Research

Professor at Sanders-Brown Center on Aging at the University of Kentucky and holds the position of Clinical Lecturer (honorary) at the University of Glasgow, adjunct Professor at Queensland University of Technology, and is a Fellow of the American Heart Association. He has published more than 40 papers in reputed journals, won several research awards, and is the inventor on several patents for his various scientific discoveries. Dr. Bix is an internationally recognized researcher as evidenced by his appointment to several distinguished grant review panels (several as chairman) and has given invited research presentations all over the world. Dr. Bix's research focus is in the role and therapeutic potential of the extracellular matrix and its receptors in stroke and vascular dementia.